The Cardiac Mapping Market in 2026

Cardiac mapping is the technique electrophysiologists use to build a real-time picture of the heart's electrical activity — locating the precise tissue driving an arrhythmia so a catheter ablation can be targeted at it rather than the surrounding chamber generally. It sits at the intersection of a diagnostic procedure and a navigation technology, and that dual nature is exactly why the business side is harder to plan than most healthcare niches: you're not opening a clinic that happens to use a device, you're building a business whose entire unit economics run through one capital-intensive piece of equipment.

The global cardiac mapping market reached an estimated $2.17 billion in 2025 and is projected to grow to $3.34 billion by 2030, a compound annual growth rate of 8.99%, according to GM Insights. Longer-range forecasts from Precedence Research put the market at $7.09 billion by 2035, and the same report notes that contact mapping — where the catheter tip physically touches heart tissue to record activation — still holds the largest technology share at 48.1% of the market in 2025, ahead of newer non-contact and ultra-high-density approaches.

Growth is being driven by three forces that matter for a business plan, not just a market report: rising diagnosed prevalence of atrial fibrillation and other arrhythmias, a documented shift toward minimally invasive procedures over open surgery, and steady technology turnover as vendors compete on mapping resolution and speed. The three systems anchoring the market are Biosense Webster's (Johnson & Johnson) CARTO 3, Abbott's EnSite X EP System, and Boston Scientific's Rhythmia HDx — all contact-based electroanatomical platforms with strong clinical evidence behind them. Medtronic entered with FDA approval of its Affera Mapping System in October 2024, and the field is still consolidating: Acutus Medical, whose AcQMap non-contact system was a genuine technical differentiator, wound down its electrophysiology business in 2025, with its assets acquired by EnChannel Medical. That consolidation is worth internalising before you write a business plan around a single-vendor equipment strategy — more on that in the mistakes section below.

For a new business, the more useful number than global market size is who actually pays and how much. Reimbursement for the procedures cardiac mapping supports — complex catheter ablations — runs through CPT codes 93609 (point-by-point mapping) and 93613 (3D electroanatomical mapping, billed as an add-on code alongside 93620, 93653, or 93656). Neither code is billed alone; both attach to a primary ablation or EP study procedure, and documentation quality directly determines whether a claim survives payer review.

North America remains the largest regional market by procedure volume, reflecting both higher diagnosed arrhythmia rates and denser EP lab infrastructure than most other regions — a relevant fact if you're weighing US expansion against a UK or EU launch first. Within the US, procedure volume also concentrates heavily in states with larger over-65 populations and established cardiology referral networks — Florida, Arizona, and Texas all combine strong demographic tailwinds with comparatively founder-friendly regulatory environments, which is worth weighing alongside the Certificate of Need detail covered later in this guide. Europe's growth is being shaped less by demographics and more by NHS and private-insurer waiting-list pressure, which has pushed a meaningful share of UK cardiac diagnostic volume toward private providers over the past several years.

Whichever geography you start in, the market data above should anchor your Industry Analysis section; the number that actually determines whether your business survives its first 18 months is the one in the next section: how much it costs to open the door.

Questions Founders Actually Ask

Before the financials, most people evaluating this niche are still working out what the business even is. These are the questions we see most often from clinicians and operators exploring a cardiac mapping venture — separate from the consumer-facing FAQ further down this page, which covers the plan and template itself.

Do I need to be an electrophysiologist to start this business?

You need one on staff or as a founding partner to perform the procedures, but ownership doesn't require it in most US states, provided you structure the entity correctly (many states restrict clinical ownership to licensed physicians under corporate practice of medicine rules — this varies enough by state that it belongs in your legal-structure section, not assumed). In the UK, CQC registration names a "registered manager," which is typically the lead clinician but does not have to be the sole owner.

What's the realistic timeline from decision to first procedure?

For a hospital-affiliated model, 4–8 months is realistic once credentialing and payer contracting are underway. For an independent outpatient suite requiring Certificate of Need approval, 12–18 months is more honest — and that timeline is exactly what most generic templates fail to model, leaving founders under-capitalised for a longer runway than they planned for.

Can this business run without owning a mapping system outright?

Yes — leasing a 3D mapping platform is common, particularly for a first-year launch, and several vendors offer per-case or subscription pricing rather than requiring a capital purchase. This materially changes the startup-cost picture covered next.

What happens if my chosen equipment vendor changes strategy or exits the market?

It's a real risk, not a hypothetical one — Acutus Medical's 2025 wind-down of its AcQMap electrophysiology assets is the clearest recent example. A well-built plan names a primary vendor and a documented fallback (a second system your staff could realistically be trained on within a defined window), rather than assuming the current market leader's position is permanent for the life of a 7- to 10-year equipment loan.

What Launch Capital Really Buys

Starting a cardiac mapping business is not a $50,000-in-a-storefront proposition, and any template that suggests otherwise hasn't priced the equipment. Depending on which of the three business models you choose (covered in the next section), total launch capital ranges from $180,000 to $2.8 million in the US (roughly £145,000 to £2.2 million in the UK). The spread is wide because the low end describes a mobile or remote diagnostics service that doesn't own a mapping system at all, while the high end describes a fully built independent outpatient suite with an in-house 3D electroanatomical platform.

For the capital-intensive end of that range — the model most people picture when they hear "cardiac mapping business" — here's where the money actually goes:

• Procedure-room build-out (radiation shielding, sterile core, imaging bay): $350,000–$900,000 (£280,000–£720,000). A dedicated EP lab facility, fully built, typically runs $1.5–$2 million once you include this and the imaging integration below — a figure most templates never mention because they're written for lower-capital service businesses.
• 3D mapping system + ablation generator (lease or capital purchase): $250,000–$1,000,000 (£200,000–£800,000). Vendor control consoles alone — Philips' EP Cockpit is one example — run around $300,000 before the mapping platform itself is added.
• Fluoroscopy/imaging integration + intracardiac echo (ICE) platform: $120,000–$400,000 (£96,000–£320,000).
• Licensing, credentialing, accreditation & insurance: $25,000–$90,000 (£20,000–£72,000).
• Staffing & working capital (first 6 months): $120,000–$350,000 (£96,000–£280,000).
• Referral-network development & marketing: $15,000–$50,000 (£12,000–£40,000).

Two things worth building into the financial model explicitly: first, per-case disposable costs (catheters, mapping consumables) commonly exceed $10,000 per procedure and are a recurring cost, not a startup cost — they belong in your cost-of-goods line, not your capex table. Second, whichever funding route you pursue, a lender or investor will expect the equipment line itemised separately from the facility line, because equipment financing and real-estate financing are usually two different instruments with different terms — see the funding section below.

Three Ways to Structure This Business

"Cardiac mapping business" covers three genuinely different operating models with very different capital requirements, timelines, and risk profiles. Picking the wrong one for your capital position is the single most common planning error we see in this niche — pick the model first, then write the plan around it, not the other way round.

The mobile/remote model looks most like the businesses already operating in this adjacent space today — companies such as Cardiac RMS, which grew from a remote-monitoring service into a registered Independent Diagnostic Testing Facility (IDTF), or ACS Diagnostics (Applied Cardiac Systems), which built a national footprint on outpatient Holter and mobile cardiac telemetry services rather than owning procedure suites. Cardiac Mobile Diagnostics, based in Los Angeles, follows a similar mobile-ultrasound model. None of these own a 3D mapping suite; they generate revenue from diagnostic interpretation and monitoring, which is a genuinely different (and far less capital-intensive) business than the outpatient ASC model.

The independent ASC model became meaningfully more attractive after CMS expanded ambulatory surgery center billing eligibility for cardiac ablation procedures — a structural shift worth flagging explicitly in your plan's market-timing section, because it changes where procedures that used to require a hospital setting can now be performed and billed.

The hospital-affiliated model sits between the two, and it's the one most first-time founders underrate. Rather than building or leasing your own facility, you negotiate access to an existing hospital's licensed EP lab and mapping system during defined block time — often a half-day or full-day slot per week — in exchange for a revenue-share or facility-fee arrangement. It sidesteps the CON question entirely in most cases, since the hospital already holds the relevant licensure, and it lets you build a referral base and case-volume track record before committing to the capital of an independent build. The trade-off is scheduling flexibility: your growth is capped by how much block time the hospital is willing to allocate, which is worth stress-testing against your Year 2–3 volume targets before you commit to this path as anything more than a bridge to independence.

Reimbursement & Unit Economics

Payer mix, not procedure volume, is the variable that makes or breaks this business. Complex ablation cases reimburse, on average, around $15,000 to $23,000 under Medicare Advantage, but the same CPT codes billed under traditional Medicare fee-for-service frequently settle at just $1,600 to $3,500 — a five-to-seven-times gap for procedurally identical work, according to AMS Solutions' electrophysiology billing guide. Commercial payer rates typically sit somewhere between those two extremes. Every business plan in this niche needs a payer-mix table, not just a blended average — a lender or investor reading only a blended figure will assume you haven't modelled the downside case.

Worked example: a two-day-per-week outpatient EP/mapping suite performing 150 mapping-guided procedures in its first year, at a blended reimbursement of roughly $15,500 per case, generates approximately $2.325 million in gross procedural revenue. Disposable costs alone — catheters, mapping consumables — commonly exceed $10,000 per case, which on 150 cases consumes roughly $1.5 million of that revenue before staffing, facility overhead, or equipment amortisation are even applied. That's why realistic Year 1 net margins in this model land around 15–20%, not the 25%+ figure a founder might assume from headline procedure pricing — margins typically improve toward 25–32% only once case volume and payer mix mature, usually by Year 2 or 3.

Revenue diversification matters more here than in most healthcare niches because of how concentrated the core procedure revenue is in a small number of high-value cases. Ancillary revenue streams worth building into the model include diagnostic EP studies that don't proceed to ablation (billed independently), device follow-up clinics for patients who received an implanted device elsewhere, and — for the mobile/remote model specifically — per-study interpretation fees, which run far lower per unit (some remote cardiac imaging read services bill in the range of $14–$50 per study) but scale with volume rather than capital.

One planning detail that's easy to miss: mapping codes 93609 and 93613 cannot be billed together on the same case, and both require a primary procedure code (93620, 93653, or 93656) to be billable at all. Get your financial model's per-case revenue assumption reviewed against current CPT bundling rules before you present it to a lender — coding errors are one of the most common reasons EP billing claims get denied.

Staffing costs deserve their own line in the model rather than a blended "overhead" percentage. A two-room suite typically needs at least one dedicated EP technologist per procedure room, procedural nursing coverage, a scheduling/prior-authorisation coordinator (prior authorisation delays are one of the more common causes of case cancellations in this niche), and billing staff experienced specifically in EP coding — generalist medical billers frequently under-code or mis-bundle mapping add-on codes, which shows up as denied claims months after the case was performed. Recruiting for these roles typically takes longer than recruiting general clinical staff, since EP-specific experience is a narrower labour pool than general cardiology support staff, and that recruiting lead time belongs in your operations timeline, not just your staffing budget line.

Funding: SBA, Growth Guarantee & Equipment Leasing

In the US, SBA 7(a) loans are the standard route for financing a medical practice at this capital level, with loan sizes ranging from $30,000 up to the program's $5 million ceiling. Practices at the scale described in this guide typically fall in the $350,001–$5,000,000 band, according to Biz2Credit's SBA loan guide for physicians. Equipment-specific financing is often structured separately from the real-estate or working-capital portion of the loan — cardiology equipment financing alone commonly runs from $80,000 (for something as modest as an echocardiography machine) up to $2 million or more for a full mapping and ablation suite, per Crestmont Capital's cardiology practice financing guide. Terms typically run 7–10 years for equipment and working capital, up to 25 years for real estate.

In the UK, the picture is different from most other BPT niches on this site: the government-backed Start Up Loans scheme caps out at £25,000, which doesn't come close to covering even the lean end of this business. The more relevant instrument is the British Business Bank's Growth Guarantee Scheme, which supports facility sizes up to £2 million with a 70% government-backed guarantee to the lender, and covers term loans (from £25,001) as well as asset finance (from £1,000) — asset finance being the more natural fit for a mapping-system lease or purchase. As of a July 2026 Chancellor's announcement, the scheme's capacity was expanded by a further £6.5 billion over four years, with facility terms extended up to 10 years for term loans and asset finance, and the annual turnover eligibility threshold raised from £45 million to £54 million — details worth citing directly in a UK-facing funding application, since they signal the scheme is actively being scaled rather than winding down. Source: British Business Bank, Growth Guarantee Scheme.

Whichever route you pursue, lenders financing equipment this specialised will want to see: a payer-mix-adjusted revenue forecast (not a single blended average), a named equipment vendor with service/support terms, and — in CON states — evidence the Certificate of Need application is either approved or realistically timelined. Our $300/£250 Research + Content package and $1,000/£800 Bespoke Plan both build these into the financial model as standard, because a generic industry-agnostic forecast rarely survives underwriting for a niche this specific.

Regulatory Pathway: FDA, MHRA/CQC & TGA

United States

• FDA clearance status of your chosen mapping system: most electroanatomical mapping systems, including the CardioInsight system, are cleared as Class II devices under 21 CFR 870.1425 (Programmable Diagnostic Computer) via the 510(k) pathway — a device-manufacturer requirement, but you need to confirm your chosen vendor's clearance status before building a plan around it.
• Certificate of Need (CON) approval — this is the requirement that catches the most new entrants off guard. As of 2025, 35 states plus Washington D.C. still require CON approval for cardiac catheterization and electrophysiology services, adding 6–18 months to your timeline and typically $15,000–$60,000 in application and legal costs. A handful of states, including Arizona and Texas, have no CON requirement at all — which is a legitimate site-selection variable, not just a compliance footnote.
• CMS ambulatory surgery center (ASC) certification, if operating the independent outpatient model, plus standard state medical facility licensure.
• CPT/billing compliance for mapping codes 93609 and 93613, which must be billed correctly alongside a primary EP or ablation procedure code.

United Kingdom

• Any mapping device sold or used in Great Britain must be registered with the MHRA and carry UKCA marking under the UK Medical Devices Regulations 2002 — a manufacturer obligation, though your plan should confirm your chosen system's registration status.
• CQC registration is required for the regulated activities of diagnostic/screening procedures and treatment of disease, disorder or injury. Processing typically takes 10–12 weeks for a complete application, and the registered manager named on the application is usually the lead clinician.
• Public liability and clinical indemnity insurance appropriate to invasive cardiac procedures — materially higher premiums than a general outpatient clinic.

Australia (representative third jurisdiction)

Cardiac mapping systems and catheters sold in Australia must be listed on the Australian Register of Therapeutic Goods (ARTG) via the Therapeutic Goods Administration (TGA), typically as Class IIb or Class III devices depending on function. Medtronic's Affera Mapping System, for example, was registered as a Class IIb device in November 2024, while several mapping catheters from Boston Scientific and Johnson & Johnson are registered as Class III. If you're modelling international expansion, confirming ARTG listing status for your chosen equipment vendor is a five-minute check that avoids a costly surprise later.

Malpractice & Facility Insurance

Insurance is worth its own budget line rather than folding it into general overhead. Invasive cardiac procedures carry materially higher malpractice premiums than diagnostic-only cardiology, and a new practice without a claims history will typically pay more than an established group until several years of clean claims data accumulate. Facility insurance for a suite housing capital equipment in the six- to seven-figure range should be underwritten with equipment-replacement value in mind, not just liability — a distinction generalist insurance brokers sometimes miss when quoting a first-time medical facility policy. Building two to three comparable quotes into your plan's appendix, rather than a single assumed premium, is the kind of detail that reassures a lender you've actually shopped this rather than estimated it.

Where New Ventures Go Wrong

Most of the mistakes below aren't clinical — they're planning and sequencing errors that show up months after the decisions that caused them were made. None of them are unusual or exotic; they're the same handful of issues our consultants see repeatedly when reviewing plans and forecasts for capital-intensive medical niches, adapted here specifically to what breaks in cardiac mapping ventures.

• Committing to a full in-house mapping suite before confirming payer mix and CON status. Acutus Medical's 2025 wind-down of its AcQMap electrophysiology business is a reminder that even well-funded, technically differentiated players can be undone by the capital intensity of this niche — a solo founder or small group is far more exposed to the same dynamics.
• Underestimating disposable costs. At $10,000+ per case, consumables can quietly consume 40%+ of procedural revenue if they're not modelled as a per-case variable cost from day one.
• Starting the CQC or CON application late. Both processes run in parallel with, not after, your lease and equipment-financing timeline. Starting them once the lease clock has already begun is the single most common cause of a launch slipping by 6+ months.
• Building the plan around one equipment vendor with no contingency. Vendor consolidation is real in this market — plan a service/support fallback, and don't assume today's market leader will hold that position for the life of your equipment lease.
• Treating reimbursement as a single number. The 5–7x gap between Medicare Advantage and Medicare FFS rates for the same CPT codes means payer mix has to be scenario-modelled before capital commitments are made, not discovered afterward.

A Realistic Launch Timeline

The timeline below is built for the capital-intensive independent outpatient model — the one most business plans in this niche get wrong by underestimating. If you're pursuing the mobile/remote diagnostics model instead, most of this compresses into 60–90 days, since you're not waiting on a CON decision or a facility build.

• Months 1–2 — Foundations: entity formation, initial lender conversations, site lease negotiation, and — in a CON state — filing the Certificate of Need application. This is also when your financial model needs to exist in a form a lender can actually underwrite, not a placeholder.
• Months 2–4 — Commitments: SBA loan underwriting proceeds in parallel with equipment vendor selection. This is the point at which you're negotiating lease-vs-purchase terms on the mapping system and getting architectural plans drawn up for the shielded procedure room.
• Months 4–8 — Build: facility construction begins, staff recruitment starts (EP technologist, procedural nursing, scheduling/billing staff), payer credentialing applications go in, and CON or CQC review continues in the background. This is typically the longest single phase and the one most founders underestimate on a first pass.
• Months 8–12 — Commissioning: equipment installation, staff training on the mapping platform, soft-launch of diagnostic-only EP studies (which don't require the full mapping workflow) to start generating cash flow before mapping-guided cases begin, and finalising payer contracts.
• Months 12–14 — First mapping-guided cases: the first ablation cases supported by 3D mapping are performed, referral relationships with local cardiologists are activated, and the practice begins tracking actual payer mix against the modelled assumption.
• Months 14–18 — Ramp to target volume: case volume climbs toward the modelled break-even point (roughly 100–150 cases/year in the worked example above), and — in CON states — any post-approval compliance reporting begins.

Two milestones deserve their own line item in your plan rather than being buried in a Gantt chart: the date payer credentialing is confirmed (nothing generates revenue before this) and the date the CON or CQC decision arrives (everything downstream depends on it). Lenders reviewing an SBA application for this niche will look specifically for both dates.

Terms Worth Knowing Before You Pitch

A lender, landlord, or investor without a clinical background will encounter these terms in your plan. Defining them cleanly — rather than assuming familiarity — is a small detail that signals the plan was written with a non-clinical reader in mind.

• Electroanatomical mapping (EAM): the general term for creating a 3D map that combines anatomical geometry with electrical activation data, used to guide ablation catheters to precise locations.
• Contact mapping: a mapping approach requiring the catheter tip to physically touch heart tissue to record each data point — the technology behind CARTO 3, EnSite X, and Rhythmia HDx.
• Non-contact mapping: a mapping approach that reconstructs electrical activity without requiring direct tissue contact at every point, often using ultrasound or multi-electrode array technology — the approach behind Acutus Medical's AcQMap.
• Catheter ablation: the therapeutic procedure that destroys (via heat, cold, or increasingly pulsed-field electroporation) the small area of heart tissue identified by mapping as the source of an arrhythmia.
• Pulsed field ablation (PFA): a newer, non-thermal ablation modality that delivers energy more selectively than traditional radiofrequency or cryoablation, with growing adoption since 2024.
• Certificate of Need (CON): a state-level regulatory approval, required in 35 states plus Washington D.C. as of 2025, confirming a community needs the healthcare service or equipment being proposed before it can be built.
• Independent Diagnostic Testing Facility (IDTF): a Medicare designation for a freestanding facility that performs diagnostic tests (including cardiac monitoring and interpretation) independent of a physician's office or hospital — the designation companies like Cardiac RMS operate under.
• Ambulatory Surgery Center (ASC): a licensed outpatient facility distinct from a hospital, increasingly relevant to this niche since CMS expanded ASC billing eligibility for cardiac ablation procedures.

Sample Business Plan Preview

Here's an extract from the kind of plan our consultants build for a cardiac mapping venture — so you can see the level of specificity we're talking about, not generic filler:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook a lender or investor in 60 seconds
• Company Overview — Legal structure, clinical ownership considerations, location, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory landscape specific to cardiac mapping
• Business Model Selection — Mobile/remote diagnostics vs. hospital-affiliated vs. independent ASC, with the capital and timeline trade-offs for each
• Payer Mix & Reimbursement Analysis — CPT-code-level revenue modelling, not a single blended assumption
• Regulatory & Licensing Plan — CON status by state (US), CQC/MHRA pathway (UK), or your relevant jurisdiction
• Operations Plan — Staffing structure, equipment vendor strategy, and case-volume ramp milestones
• Management Team — Founder/clinician bios, advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and equipment amortisation — built around the payer-mix and disposable-cost assumptions covered in this guide, not generic sector averages.

Frequently Asked Questions

Related Reading

Planning something adjacent? See our Cardiology Practice Business Plan Template for the broader practice-level version of this plan, or start with our Business Plan Writer hub if you're still deciding which service tier fits your stage.